Oncology
Multiple Myeloma
Conference Reporter® Podcast: Personalizing Frontline Therapy for Patients With High-Risk Multiple Myeloma
Despite the many advancements that have been made in the field of multiple myeloma (MM) in recent years, outcomes have lagged for patients with high-risk MM. In today’s podcast, Sagar Lonial, MD, FACP, FASCO, highlights key considerations for selecting optimal and personalized frontline therapy for high-risk MM, based on his presentation from an education session at the 2026 ASCO Annual Meeting.
Following this presentation, featured expert Sagar Lonial, MD, FACP, FASCO, was interviewed by Conference Reporter Medical Director Lauren Weinand, MD. Clinical perspectives from Dr Lonial on these findings are presented here.
Avet-Loiseau H, Davies FE, Samur MK, et al. International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;43(24):2739-2751. Published correction appears in J Clin Oncol. 2025;43(22):2553.
Lonial S. Frontline therapy in high-risk myeloma: one size does not fit all [session: High-risk multiple myeloma: redefining risk and rethinking therapy]. Session presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Morgan GJ, Lee DD, Joseph NS, Lonial S, Rodriguez-Otero P, San-Miguel JF. High-risk multiple myeloma: redefining risk and rethinking therapy. Am Soc Clin Oncol Educ Book. 2026;46(3):e517494. doi:10.1200/EDBK-26-517494
Yasar FZ, Gorshein E. Newly diagnosed high-risk multiple myeloma: outcomes and management. Adv Hematol. 2025;2025:6622365. doi:10.1155/ah/6622365
This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society of Clinical Oncology.
